Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. Michel White
Dr. Masip discussed the role of non invasive ventilation in patients with advanced and decompensated heart failure (HF). He showed that both continuous positive airway pressure ventilation (C-PAP) and non-invasive positive pressure ventilation (NIPPV) improve outcomes in patients receiving this treatment. However, there is no clear advantage to either of these modalities over the other. The key issue is to initiate treatment early, to optimise benefits. Dr. Mebazaa presented key differences between hemodialysis and ultrafiltration in patients with HF. The use of ultrafiltration is promising in this patient population, but future studies are needed to better identify the patients most likely to benefit from this therapy. Dr. Nanas outlined the beneficial effects of the early use of intra-aortic balloon pump in patients with cardiogenic shock. Unstable patients with cardiogenic shock caused by ischemic heart disease showed significantly greater benefits when treatment was initiated prior to the intervention. Dr. Mohr presented an elegant overview of the role of LV assist devices in advanced HF. Significant progress has been made in this field. Newer devices including those providing partial support are promising. Finally, Dr. Abraham presented the potential clinical utilities of implantable monitoring devices. Data from the FAST, HOMEOSTASIS and CHAMPION trials showed significant benefits in patients with severe heart failure using these devices. For example, in CHAMPION, a 38% reduction in hospitalisations for HF was reported. Additional data are needed to better select the populations most likely to benefit from these devices.
Devices for severe heart failure
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved